Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Allen

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Antibiotics (Basel, Switzerland)|March 27, 2026
Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country AnalysisEmre Yucel, Alex Soriano, Florian Thalhammer, et al.
Antibiotics (Basel, Switzerland)|February 27, 2026
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient PopulationsEmre Yücel, Alex Soriano, Florian Thalhammer, et al.
Standards in Genomic Sciences|June 17, 2011
Permanent draft genome sequence of Vibrio tubiashii strain NCIMB 1337 (ATCC19106)Ben Temperton, Simon Thomas, Karen Tait, et al.
Chemotherapy|July 26, 2014
Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costsNoemi Muszbek, Ruth Chapman, Chantelle Browne, et al.
Journal of Health Communication|July 15, 2003
When a celebrity contracts a disease: the example of Earvin "Magic" Johnson's announcement that he was HIV positiveMary K Casey, Mike Allen, Tara Emmers-Sommer, et al.
Jac-Antimicrobial Resistance|June 18, 2026
Healthcare resource utilization and readmission outcomes in patients treated with ceftolozane/tazobactam: real-world insights from the multinational SPECTRA studyEmre Yücel, Alex Soriano, Florian Thalhammer, et al.
Therapeutic Advances in Infectious Disease|February 21, 2019
Opportunities for antimicrobial stewardship in patients with acute bacterial skin and skin structure infections who are unsuitable for beta-lactam antibiotics: a multicenter prospective observational studyJonathan A T Sandoe, Kordo Saeed, Achyut Guleri, et al.
Journal of Global Antimicrobial Resistance|June 27, 2025
Real-world analysis of ceftolozane/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infectionsEmre Yucel, Alex Soriano, David L Paterson, et al.
Journal of Global Antimicrobial Resistance|February 28, 2026
Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven countriesEmre Yucel, Alex Soriano, David L Paterson, et al.
BMC Health Services Research|November 10, 2019
Estimating the effectiveness and cost-effectiveness of establishing additional endovascular Thrombectomy stroke Centres in England: a discrete event simulationPeter McMeekin, Darren Flynn, Mike Allen, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Antibiotics (Basel, Switzerland)|March 27, 2026
Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country AnalysisEmre Yucel, Alex Soriano, Florian Thalhammer, et al.
Antibiotics (Basel, Switzerland)|February 27, 2026
Clinical Outcomes and Healthcare Resource Utilization of Ceftolozane/Tazobactam in Vulnerable Patient PopulationsEmre Yücel, Alex Soriano, Florian Thalhammer, et al.
Standards in Genomic Sciences|June 17, 2011
Permanent draft genome sequence of Vibrio tubiashii strain NCIMB 1337 (ATCC19106)Ben Temperton, Simon Thomas, Karen Tait, et al.
Chemotherapy|July 26, 2014
Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costsNoemi Muszbek, Ruth Chapman, Chantelle Browne, et al.
Journal of Health Communication|July 15, 2003
When a celebrity contracts a disease: the example of Earvin "Magic" Johnson's announcement that he was HIV positiveMary K Casey, Mike Allen, Tara Emmers-Sommer, et al.
Jac-Antimicrobial Resistance|June 18, 2026
Healthcare resource utilization and readmission outcomes in patients treated with ceftolozane/tazobactam: real-world insights from the multinational SPECTRA studyEmre Yücel, Alex Soriano, Florian Thalhammer, et al.
Therapeutic Advances in Infectious Disease|February 21, 2019
Opportunities for antimicrobial stewardship in patients with acute bacterial skin and skin structure infections who are unsuitable for beta-lactam antibiotics: a multicenter prospective observational studyJonathan A T Sandoe, Kordo Saeed, Achyut Guleri, et al.
Journal of Global Antimicrobial Resistance|June 27, 2025
Real-world analysis of ceftolozane/tazobactam prescribing patterns and effectiveness: SPECTRA analysis on chronic pulmonary diseases and respiratory-related infectionsEmre Yucel, Alex Soriano, David L Paterson, et al.
Journal of Global Antimicrobial Resistance|February 28, 2026
Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven countriesEmre Yucel, Alex Soriano, David L Paterson, et al.
BMC Health Services Research|November 10, 2019
Estimating the effectiveness and cost-effectiveness of establishing additional endovascular Thrombectomy stroke Centres in England: a discrete event simulationPeter McMeekin, Darren Flynn, Mike Allen, et al.
Pageof 4